VF
SABS icon

Virtu Financial’s SAB Biotherapeutics SABS Stock Holding History

Virtu Financial’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$145K Buy
+37,943
New +$151K 0.01% 1113
2025
Q4 		– Sell
-19,982
Closed -$40K – 2154
2025
Q3 		$40K Buy
+19,982
New +$45.2K ﹤0.01% 1166
2023
Q3 		– Sell
-2,490
Closed -$21K – 1818
2023
Q2 		$21K Buy
2,490
+989
+66% +$8.1K ﹤0.01% 1254
2023
Q1 		$7K Buy
+1,501
New +$9.49K ﹤0.01% 1377
2022
Q1 		– Sell
-1,538
Closed -$120K – 1964
2021
Q4 		$120K Buy
+1,538
New +$144K 0.01% 1054

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Virtu Financial's SABS Position: Q1 2026 in Review

Virtu Financial opened a new position in SAB Biotherapeutics (SABS) in Q1 2026: 37,943 shares worth $145K. The stake represents 0.01% of the portfolio and ranks #1113 among its holdings. This is a return to the name: Virtu Financial previously reported a position in SABS as recently as Q3 2025.

Virtu Financial first reported a position in SABS in Q4 2021 and has held it in 5 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Virtu Financial held 37,943 shares of SAB Biotherapeutics worth $145K as of Q1 2026.
  • SAB Biotherapeutics was a new Virtu Financial position in Q1 2026.
  • SAB Biotherapeutics made up 0.01% of Virtu Financial's portfolio in Q1 2026, its #1113 holding.
  • Virtu Financial first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 5 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.